Antiarrhythmic Drugs


Book Description

This volume reviews current and potential future therapies for arrhythmias. It is a highly practical guide for the use of pharmaceuticals in the management of the discipline, and has been written in a simple quick-access format. Antiarrhythmic Drugs builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis.




Antiarrhythmic Drugs


Book Description

If you prescribe for patients with arrhythmias, you will want to keep this valuable paperback close at hand. The Second Edition of this valuable reference responds to changes in the available medications as well as in the way they are currently used. The book reviews everything you need to understand and prescribe today’s antiarrhythmic drugs: mechanisms of cardiac arrhythmias and how antiarrhythmic drugs alter those arrhythmias, including common adverse effects which factors to consider in using these drugs for treatment of supraventricular tachyarrhythmias, ventricular arrhythmias, and arrhythmias in pregnancy a detailed review of atrial fibrillation to help you make decisions for patient management in this complicated area Dr. Fogoros considers all the most recent drugs, plus promising drugs under investigation, to give you a full picture of therapeutic options. With Antiarrhythmic Drugs: A Practical Guide, Second Edition, you will have dependable information on how each drug works and when each one is indicated so you can give your patients the best possible treatment.




Pediatric Cardiac Surgery


Book Description

Pediatric cardiac surgery is a dynamic, fast-moving field. Busy practitioners, like you, need clear and comprehensive guidance you can rely on to ensure optimal patient care. For over 25 years Pediatric Cardiac Surgery has been the gold-standard reference for pediatric and adult congenital heart surgeons, pediatric and congenital cardiologists, intensivists, anesthesiologists, residents and nurses. Now, in this thoroughly revised fourth edition, you again get trusted, complete coverage of the field with timely new features and expert reviews of critical topics including heart transplantation, emerging modalities for diagnosing congenital heart and tracheal defects, the surgical technique of Fontan conversion with arrhythmia surgery, the medical challenges of managing adult CHD patients, and more. This new edition includes: Contributions from over 65 world-renowned experts More beautiful illustrations, by renowned medical illustrator Rachid Idriss, which have brought acclaim to previous editions Reviews of the embryology, physical findings, diagnostic criteria, and therapeutic choices for each disease entity and describes the latest in surgical techniques in each chapter All-new chapters that guide readers through new treatment options and other key developments since the publication of the third edition highlighting recent advances in congenital heart surgery. All-new new chapters that review advances in right ventricular to pulmonary artery conduits, arrhythmia surgery, double outlet ventricles, and adult congenital heart disease, among other key topics.




Antiarrhythmic Drugs


Book Description

The development of a new antiarrhythmic drug involves many people with disparate skills. The organic chemist who makes it is guided not only by the structure-action relations of previous compounds, but by anticipation of a requirement for a particular type of action. In fact several of the best-known antiarrhythmics, including lidocaine, mexiletine, amiodarone and verapamil, were originally synthesized for other purposes. Physicians have to determine whether the new drug works, and pharma cologists how it works. For some years I have believed that there was room for a work which could be understood by all these groups and which could enlighten each about the point of view of the others. Thus when I was invited by Springer-Verlag to prepare a volume in their series Handbook of Experimental Pharmacology, I already had a firm conception of what its form should be. In any multi-author work there are two objectives which cannot always readily be reconciled. The first is to select topics which would relate to each other in a coherent manner. to give a logical and orderly shape to the volume as a whole. The second is to offer authors the greatest possible freedom to express themselves as they wish. When the general design was complete, prospective contributors were invited to write specific chapters, being provided with a complete list of their coauthors and chosen topics, so that they could avoid overlap.




Integrating Cardiology for Nuclear Medicine Physicians


Book Description

Nuclear cardiology is no longer a medical discipline residing solely in nuclear medicine. This is the first book to recognize this fact by integrating in-depth information from both the clinical cardiology and nuclear cardiology literature, and acknowledging cardiovascular medicine as the fundamental knowledge base needed for the practice of nuclear cardiology. The book is designed to increase the practitioner's knowledge of cardiovascular medicine, thereby enhancing the quality of interpretations through improved accuracy and clinical relevance.The text is divided into four sections covering all major topics in cardiology and nuclear cardiology: Basic Sciences and Cardiovascular Diseases Conventional Diagnostic Modalities Nuclear Cardiology Management of Cardiovascular Diseases




Neurocritical Care Pharmacotherapy


Book Description

Neurocritical Care Pharmacotherapy: A Clinican's Guide is a practical, succinct but comprehensive pharmacy handbook provides up-to-date clinical guidance on the effective selection, prescription, and usage of neurocritical care drugs for patients with acute neurologic illnesses. The treatment of the critically ill neurologic patient is often difficult, specialized, and includes drugs infrequently used in other intensive care units such as antiepileptic drugs, osmotic agents or acute immunotherapy such as intravenous immunoglobulin and plasma exchange. This text discusses choosing the right combination of drugs; how to correctly prescribe and administer the drugs; how to monitor drug efficacy and side effects; how neurocritical care drugs interact with other medications; and comprehensive coverage of current treatment options. Key Feature of this Manual Include - A brief discussion of the basic pharmacology of each neurocritical drug, with an emphasis on how to select and use these drugs in multiple clinical contexts. - 150 drugs accompanied by a diagram for quick comprehension and drug administration guides. - Unique blending of expertise of neurointensivist with a critical care pharmacist to provide a vital resource for both specialities - References for further reading that are oriented toward utility in clinical practice.




Antiarrhythmic Drugs


Book Description

The past 10 years have seen a remarkable change in the approach to cardiac arrhythmias, from a position of confidence and a feeling of well-being about pharmacological treatment to a situation in which there is now marked uncertainty and general apprehension about the role of antiarrhythmic drugs. Until relatively recently the prevailing concept in antiarrhythmic therapy was that arrhythmias could be controlled by drugs which slowed conduction or suppressed automaticity, goals well served by the sodium channel-blocking drugs and glycosides. Drug re search was based largely on the development of agents mimicking those already available, but with greater efficacy, fewer side effects or a more favourable phar macokinetic profile. The CAST trial stands out as a landmark in the evolution of arrhytmia manage ment; rarely has a single trial had such a profound impact not only on clinical prac tice, but also on the whole approach of those involved in the research, development and regulation of antiarrhythmic drugs. The results of the CAST trial, designed to redress the shortcomings of earlier trials which had failed to demonstrate the anticipated improvement in mortality post-myocardial infarction with the use of class I agents, are well known. The CAST and CAST II showed an increase in mor tality associated with the active agent (encainide, flecainide or morizicine) com pared to placebo treatment. They firmly established the potential danger in the use of class I drugs.




Electrical Diseases of the Heart


Book Description

This book provides a unique contemporary and succinct distillation of the current status of recently delineated electrical diseases of the heart, emphasizing their common and diverse clinical features. The latest developments in the field of experimental and clinical cardiac electrophysiology, genetics, pharmacology and interventional therapies of various clinical arrhythmogenic entities are featured and discussed in terms of recent advances in basic and clinical science. The book is divided into seven major parts. Each part consists of chapters (total of 64) dealing with related topics.




Cardiology Explained


Book Description

One of the most time-consuming tasks in clinical medicine is seeking the opinions of specialist colleagues. There is a pressure not only to make referrals appropriate but also to summarize the case in the language of the specialist. This book explains basic physiologic and pathophysiologic mechanisms of cardiovascular disease in a straightforward manner, gives guidelines as to when referral is appropriate, and, uniquely, explains what the specialist is likely to do. It is ideal for any hospital doctor, generalist, or even senior medical student who may need a cardiology opinion, or for that ma.




The Evaluation of New Antiarrhythmic Drugs


Book Description

Thus, there are now several chronic canine myocardial infarction ventricular tachyarrhythmia models which are available for the evaluation of new antiarrhythmic drugs (Table I). The available models fulfill many, but not all of the requirements for an ideal chronic arrhythmia model (Table 11). The sustained arrhythmias initiated in these models using programmed pacing presumably have the same localized reentrant mechanism that characterizes chronic human myocardial infarction and chronic coronary 26 artery disease. However, these models are not suitable for determining whether a new drug will abolish spontaneous ly-occurring PVCs. In addition, these models are of unproven value in the study of acute spontaneously occurring sudden death; although recently initiated, provocative work may shed further light on this subject. Most importantly, the available models do seem well-suited to the evaluation of new drugs intended for use in chronic coronary artery disease patients at risk for sustained reentrant ventricular tachycardia or VF. Notably, the results of preliminary electropharmacologic studies in these canine models parallel closely those findings reported in human patients with sustained life-threatening ventricu lar tachyarrhythmias (Table Ill). Therefore, increased use of these chronic models for new antiarrhythmic drug testing is strongly recommended. TABLE II Ideal vs Available Chronic Canine - Arrhythmia Models Ideal Available 1. (a) Arrhythmia mechanism comparable to Yes patients with chronic CAD: Reentry (b) Pathophysiology similar (e. g. , atherogenic CAD) No 2. Susceptible to: (a) spontaneous PVCs No l No (b) spontaneous VT/VF (c) inducible VT/VF Yes 3.